{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T10:57:16Z","timestamp":1793444236722,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2013,12,6]],"date-time":"2013-12-06T00:00:00Z","timestamp":1386288000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2013,12,6]],"date-time":"2013-12-06T00:00:00Z","timestamp":1386288000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Introduction<\/jats:title>\n                        <jats:p>The FMS-related tyrosine kinase 3 ligand (Flt3L)\/CD135 axis plays a fundamental role in proliferation and differentiation of dendritic cells (DCs). As DCs play an important role in rheumatoid arthritis (RA) immunopathology we studied in detail the Flt3L\/CD135 axis in RA patients.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>The levels of Flt3L in (paired) serum and synovial fluid (SF) were quantified by enzyme-link immunosorbent assay (ELISA). Expression of Flt3L and CD135 in paired peripheral blood mononuclear cells (PBMCs) and synovial fluid mononuclear cells (SFMCs) was quantified by fluorescence-activated cell sorting (FACS). The expression of Flt3L, CD135 and TNF-Converting Enzyme (TACE) in synovial tissues (STs) and <jats:italic>in vitro<\/jats:italic> polarized macrophages and monocyte-derived DCs (Mo-DCs) was assessed by quantitative PCR (qPCR). CD135 ST expression was evaluated by immunohistochemistry and TACE ST expression was assessed by immunofluorescence. Flt3L serum levels were assessed in RA patients treated with oral prednisolone or adalimumab.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>Flt3L levels in RA serum, SF and ST were significantly elevated compared to gout patients and healthy individuals (HI). RA SF monocytes, natural killer cells and DCs expressed high levels of Flt3L and CD135 compared to HI. RA ST CD68<jats:sup>+<\/jats:sup> and CD163<jats:sup>+<\/jats:sup> macrophages, CD55<jats:sup>+<\/jats:sup> fibroblast-like synoviocytes (FLS), CD31<jats:sup>+<\/jats:sup> endothelial cells or infiltrating monocytes and CD19<jats:sup>+<\/jats:sup> B cells co-expressed TACE. IFN-\u03b3-differentiated macrophages expressed higher levels of Flt3L compared to other polarized macrophages. Importantly, Flt3L serum levels were reduced by effective therapy.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusions<\/jats:title>\n                        <jats:p>The Flt3L\/CD135 axis is active in RA patients and is responsive to both prednisolone and adalimumab treatment. Conceivably, this ligand receptor pair represents a novel therapeutic target.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/ar4403","type":"journal-article","created":{"date-parts":[[2013,12,6]],"date-time":"2013-12-06T10:03:10Z","timestamp":1386324190000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["FMS-related tyrosine kinase 3 ligand (Flt3L)\/CD135 axis in rheumatoid arthritis"],"prefix":"10.1186","volume":"15","author":[{"given":"Maria I","family":"Ramos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel Garcia","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saida","family":"Aarrass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boy","family":"Helder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pleun","family":"Broekstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daan M","family":"Gerlag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris A","family":"Reedquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul Peter","family":"Tak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C","family":"Lebre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,12,6]]},"reference":[{"key":"4448_CR1","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1056\/NEJMra1004965","volume":"365","author":"IB McInnes","year":"2011","unstructured":"McInnes IB, Schett G: The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011, 365: 2205-2219. 10.1056\/NEJMra1004965.","journal-title":"N Engl J Med"},{"key":"4448_CR2","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1002\/1529-0131(200012)43:12<2619::AID-ANR1>3.0.CO;2-V","volume":"43","author":"PP Tak","year":"2000","unstructured":"Tak PP, Bresnihan B: The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis. Arthritis Rheum. 2000, 43: 2619-2633. 10.1002\/1529-0131(200012)43:12<2619::AID-ANR1>3.0.CO;2-V.","journal-title":"Arthritis Rheum"},{"key":"4448_CR3","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/art.1780400206","volume":"40","author":"PP Tak","year":"1997","unstructured":"Tak PP, Smeets TJ, Daha MR, Kluin PM, Meijers KA, Brand R, Meinders AE, Breedveld FC: Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis Rheum. 1997, 40: 217-225. 10.1002\/art.1780400206.","journal-title":"Arthritis Rheum"},{"key":"4448_CR4","doi-asserted-by":"publisher","first-page":"R15","DOI":"10.1186\/ar1864","volume":"8","author":"SL Jongbloed","year":"2006","unstructured":"Jongbloed SL, Lebre MC, Fraser AR, Gracie JA, Sturrock RD, Tak PP, McInnes IB: Enumeration and phenotypical analysis of distinct dendritic cell subsets in psoriatic arthritis and rheumatoid arthritis. Arthritis Res Ther. 2006, 8: R15-10.1186\/ar1864.","journal-title":"Arthritis Res Ther"},{"key":"4448_CR5","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/nature06175","volume":"449","author":"RM Steinman","year":"2007","unstructured":"Steinman RM, Banchereau J: Taking dendritic cells into medicine. Nature. 2007, 449: 419-426. 10.1038\/nature06175.","journal-title":"Nature"},{"key":"4448_CR6","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1146\/annurev.iy.09.040191.001415","volume":"9","author":"RM Steinman","year":"1991","unstructured":"Steinman RM: The dendritic cell system and its role in immunogenicity. Annu Rev Immunol. 1991, 9: 271-296. 10.1146\/annurev.iy.09.040191.001415.","journal-title":"Annu Rev Immunol"},{"key":"4448_CR7","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/S0952-7915(02)00399-0","volume":"14","author":"SJ Turley","year":"2002","unstructured":"Turley SJ: Dendritic cells: inciting and inhibiting autoimmunity. Curr Opin Immunol. 2002, 14: 765-770. 10.1016\/S0952-7915(02)00399-0.","journal-title":"Curr Opin Immunol"},{"key":"4448_CR8","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/1529-0131(200004)43:4<791::AID-ANR9>3.0.CO;2-E","volume":"43","author":"AR Pettit","year":"2000","unstructured":"Pettit AR, MacDonald KP, O\u2019Sullivan B, Thomas R: Differentiated dendritic cells expressing nuclear RelB are predominantly located in rheumatoid synovial tissue perivascular mononuclear cell aggregates. Arthritis Rheum. 2000, 43: 791-800. 10.1002\/1529-0131(200004)43:4<791::AID-ANR9>3.0.CO;2-E.","journal-title":"Arthritis Rheum"},{"key":"4448_CR9","doi-asserted-by":"publisher","first-page":"940","DOI":"10.2353\/ajpath.2008.070703","volume":"172","author":"MC Lebre","year":"2008","unstructured":"Lebre MC, Jongbloed SL, Tas SW, Smeets TJ, McInnes IB, Tak PP: Rheumatoid arthritis synovium contains two subsets of CD83\u2013DC\u2013. Am J Pathol. 2008, 172: 940-950. 10.2353\/ajpath.2008.070703.","journal-title":"Am J Pathol"},{"key":"4448_CR10","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/nri1786","volume":"6","author":"F Aloisi","year":"2006","unstructured":"Aloisi F, Pujol-Borrell R: Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol. 2006, 6: 205-217. 10.1038\/nri1786.","journal-title":"Nat Rev Immunol"},{"key":"4448_CR11","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood.V95.11.3489","volume":"95","author":"HJ McKenna","year":"2000","unstructured":"McKenna HJ, Stocking KL, Miller RE, Brasel K, De Smedt T, Maraskovsky E, Maliszewski CR, Lynch DH, Smith J, Pulendran B, Roux ER, Teepe M, Lyman SD, Peschon JJ: Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood. 2000, 95: 3489-3497.","journal-title":"Blood"},{"key":"4448_CR12","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S1074-7613(03)00332-7","volume":"19","author":"Y Laouar","year":"2003","unstructured":"Laouar Y, Welte T, Fu XY, Flavell RA: STAT3 is required for Flt3L-dependent dendritic cell differentiation. Immunity. 2003, 19: 903-912. 10.1016\/S1074-7613(03)00332-7.","journal-title":"Immunity"},{"key":"4448_CR13","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1182\/blood.V96.3.878","volume":"96","author":"E Maraskovsky","year":"2000","unstructured":"Maraskovsky E, Daro E, Roux E, Teepe M, Maliszewski CR, Hoek J, Caron D, Lebsack ME, McKenna HJ: In vivo generation of human dendritic cell subsets by Flt3 ligand. Blood. 2000, 96: 878-884.","journal-title":"Blood"},{"key":"4448_CR14","first-page":"149","volume":"10","author":"SD Lyman","year":"1995","unstructured":"Lyman SD, James L, Escobar S, Downey H, De Vries P, Brasel K, Stocking K, Beckmann MP, Copeland NG, Cleveland LS: Identification of soluble and membrane-bound isoforms of the murine flt3 ligand generated by alternative splicing of mRNAs. Oncogene. 1995, 10: 149-157.","journal-title":"Oncogene"},{"key":"4448_CR15","doi-asserted-by":"publisher","first-page":"7408","DOI":"10.4049\/jimmunol.0801931","volume":"182","author":"K Horiuchi","year":"2009","unstructured":"Horiuchi K, Morioka H, Takaishi H, Akiyama H, Blobel CP, Toyama Y: Ectodomain shedding of FLT3 ligand is mediated by TNF-alpha converting enzyme. J Immunol. 2009, 182: 7408-7414. 10.4049\/jimmunol.0801931.","journal-title":"J Immunol"},{"key":"4448_CR16","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/385729a0","volume":"385","author":"RA Black","year":"1997","unstructured":"Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Cerretti DP: A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature. 1997, 385: 729-733. 10.1038\/385729a0.","journal-title":"Nature"},{"key":"4448_CR17","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.it.2007.10.009","volume":"29","author":"G Murphy","year":"2008","unstructured":"Murphy G, Murthy A, Khokha R: Clipping, shedding and RIPping keep immunity on cue. Trends Immunol. 2008, 29: 75-82. 10.1016\/j.it.2007.10.009.","journal-title":"Trends Immunol"},{"key":"4448_CR18","first-page":"238","volume":"10","author":"O Rosnet","year":"1996","unstructured":"Rosnet O, Buhring HJ, Marchetto S, Rappold I, Lavagna C, Sainty D, Arnoulet C, Chabannon C, Kanz L, Hannum C, Birnbaum D: Human FLT3\/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. Leukemia. 1996, 10: 238-248.","journal-title":"Leukemia"},{"key":"4448_CR19","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1006\/cyto.1999.0540","volume":"12","author":"MA Antonysamy","year":"2000","unstructured":"Antonysamy MA, Thomson AW: Flt3 ligand (FL) and its influence on immune reactivity. Cytokine. 2000, 12: 87-100. 10.1006\/cyto.1999.0540.","journal-title":"Cytokine"},{"key":"4448_CR20","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/ni.1615","volume":"9","author":"C Waskow","year":"2008","unstructured":"Waskow C, Liu K, Darrasse-Jeze G, Guermonprez P, Ginhoux F, Merad M, Shengelia T, Yao K, Nussenzweig M: The receptor tyrosine kinase Flt3 is required for dendritic cell development in peripheral lymphoid tissues. Nat Immunol. 2008, 9: 676-683. 10.1038\/ni.1615.","journal-title":"Nat Immunol"},{"key":"4448_CR21","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1084\/jem.20030323","volume":"198","author":"H Karsunky","year":"2003","unstructured":"Karsunky H, Merad M, Cozzio A, Weissman IL, Manz MG: Flt3 ligand regulates dendritic cell development from Flt3+ lymphoid and myeloid-committed progenitors to Flt3+ dendritic cells in vivo. J Exp Med. 2003, 198: 305-313. 10.1084\/jem.20030323.","journal-title":"J Exp Med"},{"key":"4448_CR22","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1189\/jlb.1110640","volume":"90","author":"M Dehlin","year":"2011","unstructured":"Dehlin M, Andersson S, Erlandsson M, Brisslert M, Bokarewa M: Inhibition of fms-like tyrosine kinase 3 alleviates experimental arthritis by reducing formation of dendritic cells and antigen presentation. J Leukoc Biol. 2011, 90: 811-817. 10.1189\/jlb.1110640.","journal-title":"J Leukoc Biol"},{"key":"4448_CR23","doi-asserted-by":"publisher","first-page":"e3633","DOI":"10.1371\/journal.pone.0003633","volume":"3","author":"M Dehlin","year":"2008","unstructured":"Dehlin M, Bokarewa M, Rottapel R, Foster SJ, Magnusson M, Dahlberg LE, Tarkowski A: Intra-articular fms-like tyrosine kinase 3 ligand expression is a driving force in induction and progression of arthritis. PLoS One. 2008, 3: e3633-10.1371\/journal.pone.0003633.","journal-title":"PLoS One"},{"key":"4448_CR24","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.138461","volume":"2010","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Menard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsky J, Wolfe F, Hawker G: Rheumatoid arthritis classification criteria: an American college of rheumatology\/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2010, 2010: 1580-1588.","journal-title":"Ann Rheum Dis"},{"key":"4448_CR25","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1136\/ard.2010.139550","volume":"70","author":"MG van de Sande","year":"2011","unstructured":"van de Sande MG, Gerlag DM, Lodde BM, van Baarsen LG, Alivernini S, Codullo V, Felea I, Vieira-Sousa E, Fearon U, Reece R, Montecucco C, Veale DJ, Pitzalis C, Emery P, Klareskog L, McInnes IB, Tak PP: Evaluating antirheumatic treatments using synovial biopsy: a recommendation for standardisation to be used in clinical trials. Ann Rheum Dis. 2011, 70: 423-427. 10.1136\/ard.2010.139550.","journal-title":"Ann Rheum Dis"},{"key":"4448_CR26","doi-asserted-by":"publisher","first-page":"3783","DOI":"10.1002\/art.20664","volume":"50","author":"DM Gerlag","year":"2004","unstructured":"Gerlag DM, Haringman JJ, Smeets TJ, Zwinderman AH, Kraan MC, Laud PJ, Morgan S, Nash AF, Tak PP: Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis. Arthritis Rheum. 2004, 50: 3783-3791. 10.1002\/art.20664.","journal-title":"Arthritis Rheum"},{"key":"4448_CR27","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1136\/ard.2007.086728","volume":"68","author":"CA Wijbrandts","year":"2009","unstructured":"Wijbrandts CA, van Leuven SI, Boom HD, Gerlag DM, Stroes EG, Kastelein JJ, Tak PP: Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritis. Ann Rheum Dis. 2009, 68: 1316-1321. 10.1136\/ard.2007.086728.","journal-title":"Ann Rheum Dis"},{"key":"4448_CR28","doi-asserted-by":"publisher","first-page":"R862","DOI":"10.1186\/ar1757","volume":"7","author":"JJ Haringman","year":"2005","unstructured":"Haringman JJ, Vinkenoog M, Gerlag DM, Smeets TJ, Zwinderman AH, Tak PP: Reliability of computerized image analysis for the evaluation of serial synovial biopsies in randomized controlled trials in rheumatoid arthritis. Arthritis Res Ther. 2005, 7: R862-R867. 10.1186\/ar1757.","journal-title":"Arthritis Res Ther"},{"key":"4448_CR29","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1182\/blood.V93.8.2595","volume":"93","author":"E Chklovskaia","year":"1999","unstructured":"Chklovskaia E, Jansen W, Nissen C, Lyman SD, Rahner C, Landmann L, Wodnar-Filipowicz A: Mechanism of flt3 ligand expression in bone marrow failure: translocation from intracellular stores to the surface of T lymphocytes after chemotherapy-induced suppression of hematopoiesis. Blood. 1999, 93: 2595-2604.","journal-title":"Blood"},{"key":"4448_CR30","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1182\/blood.V97.4.1027","volume":"97","author":"E Chklovskaia","year":"2001","unstructured":"Chklovskaia E, Nissen C, Landmann L, Rahner C, Pfister O, Wodnar-Filipowicz A: Cell-surface trafficking and release of flt3 ligand from T lymphocytes is induced by common cytokine receptor gamma-chain signaling and inhibited by cyclosporin A. Blood. 2001, 97: 1027-1034. 10.1182\/blood.V97.4.1027.","journal-title":"Blood"},{"key":"4448_CR31","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1182\/blood-2005-10-006643","volume":"108","author":"R Ceredig","year":"2006","unstructured":"Ceredig R, Rauch M, Balciunaite G, Rolink AG: Increasing Flt3L availability alters composition of a novel bone marrow lymphoid progenitor compartment. Blood. 2006, 108: 1216-1222. 10.1182\/blood-2005-10-006643.","journal-title":"Blood"},{"key":"4448_CR32","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1146\/annurev.immunol.021908.132557","volume":"27","author":"C Auffray","year":"2009","unstructured":"Auffray C, Sieweke MH, Geissmann F: Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol. 2009, 27: 669-692. 10.1146\/annurev.immunol.021908.132557.","journal-title":"Annu Rev Immunol"},{"key":"4448_CR33","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1038\/nri1733","volume":"5","author":"S Gordon","year":"2005","unstructured":"Gordon S, Taylor PR: Monocyte and macrophage heterogeneity. Nat Rev Immunol. 2005, 5: 953-964. 10.1038\/nri1733.","journal-title":"Nat Rev Immunol"},{"key":"4448_CR34","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1182\/blood.V98.9.2707","volume":"98","author":"JM Lean","year":"2001","unstructured":"Lean JM, Fuller K, Chambers TJ: FLT3 ligand can substitute for macrophage colony-stimulating factor in support of osteoclast differentiation and function. Blood. 2001, 98: 2707-2713. 10.1182\/blood.V98.9.2707.","journal-title":"Blood"},{"key":"4448_CR35","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1182\/blood-2003-06-1969","volume":"103","author":"R Zheng","year":"2004","unstructured":"Zheng R, Levis M, Piloto O, Brown P, Baldwin BR, Gorin NC, Beran M, Zhu Z, Ludwig D, Hicklin D, Witte L, Li Y, Small D: FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells. Blood. 2004, 103: 267-274. 10.1182\/blood-2003-06-1969.","journal-title":"Blood"},{"key":"4448_CR36","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1182\/blood.V91.4.1101","volume":"91","author":"SD Lyman","year":"1998","unstructured":"Lyman SD, Jacobsen SE: c-kit ligand and Flt3 ligand: stem\/progenitor cell factors with overlapping yet distinct activities. Blood. 1998, 91: 1101-1134.","journal-title":"Blood"},{"key":"4448_CR37","first-page":"1756","volume":"28","author":"S Ohta","year":"2001","unstructured":"Ohta S, Harigai M, Tanaka M, Kawaguchi Y, Sugiura T, Takagi K, Fukasawa C, Hara M, Kamatani N: Tumor necrosis factor-alpha (TNF-alpha) converting enzyme contributes to production of TNF-alpha in synovial tissues from patients with rheumatoid arthritis. J Rheumatol. 2001, 28: 1756-1763.","journal-title":"J Rheumatol"},{"key":"4448_CR38","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1124\/jpet.103.059675","volume":"309","author":"Y Zhang","year":"2004","unstructured":"Zhang Y, Xu J, Levin J, Hegen M, Li G, Robertshaw H, Brennan F, Cummons T, Clarke D, Vansell N, Nickerson-Nutter C, Barone D, Mohler K, Black R, Skotnicki J, Gibbons J, Feldmann M, Frost P, Larsen G, Lin LL: Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecar boxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme\/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis. J Pharmacol Exp Ther. 2004, 309: 348-355. 10.1124\/jpet.103.059675.","journal-title":"J Pharmacol Exp Ther"},{"key":"4448_CR39","doi-asserted-by":"publisher","first-page":"569","DOI":"10.2174\/1381612053381927","volume":"11","author":"Y Ma","year":"2005","unstructured":"Ma Y, Pope RM: The role of macrophages in rheumatoid arthritis. Curr Pharm Des. 2005, 11: 569-580. 10.2174\/1381612053381927.","journal-title":"Curr Pharm Des"},{"key":"4448_CR40","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/art.1780390116","volume":"39","author":"D Mulherin","year":"1996","unstructured":"Mulherin D, Fitzgerald O, Bresnihan B: Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. Arthritis Rheum. 1996, 39: 115-124. 10.1002\/art.1780390116.","journal-title":"Arthritis Rheum"},{"key":"4448_CR41","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.immuni.2010.05.007","volume":"32","author":"S Gordon","year":"2010","unstructured":"Gordon S, Martinez FO: Alternative activation of macrophages: mechanism and functions. Immunity. 2010, 32: 593-604. 10.1016\/j.immuni.2010.05.007.","journal-title":"Immunity"},{"key":"4448_CR42","doi-asserted-by":"publisher","first-page":"6166","DOI":"10.4049\/jimmunol.164.12.6166","volume":"164","author":"CD Mills","year":"2000","unstructured":"Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM: M-1\/M-2 macrophages and the Th1\/Th2 paradigm. J Immunol. 2000, 164: 6166-6173.","journal-title":"J Immunol"},{"key":"4448_CR43","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1136\/ard.2004.029751","volume":"64","author":"JJ Haringman","year":"2005","unstructured":"Haringman JJ, Gerlag DM, Zwinderman AH, Smeets TJ, Kraan MC, Baeten D, McInnes IB, Bresnihan B, Tak PP: Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2005, 64: 834-838. 10.1136\/ard.2004.029751.","journal-title":"Ann Rheum Dis"},{"key":"4448_CR44","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1002\/art.27638","volume":"62","author":"KD Deane","year":"2010","unstructured":"Deane KD, O\u2019Donnell CI, Hueber W, Majka DS, Lazar AA, Derber LA, Gilliland WR, Edison JD, Norris JM, Robinson WH, Holers VM: The number of elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts time to diagnosis in an age-dependent manner. Arthritis Rheum. 2010, 62: 3161-3172. 10.1002\/art.27638.","journal-title":"Arthritis Rheum"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar4403.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/ar4403\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar4403.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T10:07:55Z","timestamp":1728382075000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/ar4403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,6]]},"references-count":44,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2013,12]]}},"alternative-id":["4448"],"URL":"https:\/\/doi.org\/10.1186\/ar4403","relation":{},"ISSN":["1478-6354"],"issn-type":[{"value":"1478-6354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,6]]},"assertion":[{"value":"25 July 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"R209"}}